Plus   Neg

Sage Therapeutics (SAGE) Dropped After Phase 3 Study Failed

Sage Therapeutics (SAGE) announced Tuesday morning that its Phase 3 trial of brexanolone in the treatment super-refractory status epilepticus failed to meet the primary endpoint.

Sage Therapeutics gapped open sharply lower Tuesday, but recovered ground during the first half of the morning. Shares finished with a loss of 12.12 at $76.40 on the highest volume of the year. Sage Therapeutics dropped to a 2-week low.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT